- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Selecting Among Third-Line Therapies in Clinical Practice for mCRC
Panelists discuss how efficacy, safety, quality of life, and patient-specific factors drive selection among third-line therapies in metastatic colorectal cancer.
Panelists emphasize the complexity of choosing among available third-line therapies, noting that no single option fits all patients. Clinical decision-making weighs efficacy, safety, quality of life, and individual disease characteristics such as molecular profile and comorbidities.
They describe how some patients may be better candidates for trifluridine/tipiracil (FTD/TPI) earlier in the sequence due to tolerability whereas others may benefit more from fruquintinib or regorafenib based on clinical presentation or prior treatment exposures.
The discussion highlights that personalization remains essential, with therapy choice influenced not only by trial data but also by patient-specific goals and real-world circumstances.
